- Home
- TRVI vs ANNX Comparison
TRVI vs ANNX Comparison
Compare TRVI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- ANNX
- Stock Information
- Founded
- TRVI 2011
- ANNX 2011
- Country
- TRVI United States
- ANNX United States
- Employees
- TRVI N/A
- ANNX N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- ANNX Health Care
- Exchange
- TRVI Nasdaq
- ANNX Nasdaq
- Market Cap
- TRVI 383.4M
- ANNX 362.4M
- IPO Year
- TRVI 2019
- ANNX 2020
- Fundamental
- Price
- TRVI $6.61
- ANNX $1.60
- Analyst Decision
- TRVI Strong Buy
- ANNX Strong Buy
- Analyst Count
- TRVI 8
- ANNX 5
- Target Price
- TRVI $17.56
- ANNX $18.67
- AVG Volume (30 Days)
- TRVI 1.3M
- ANNX 1.6M
- Earning Date
- TRVI 05-08-2025
- ANNX 05-20-2025
- Dividend Yield
- TRVI N/A
- ANNX N/A
- EPS Growth
- TRVI N/A
- ANNX N/A
- EPS
- TRVI N/A
- ANNX N/A
- Revenue
- TRVI N/A
- ANNX N/A
- Revenue This Year
- TRVI N/A
- ANNX N/A
- Revenue Next Year
- TRVI N/A
- ANNX N/A
- P/E Ratio
- TRVI N/A
- ANNX N/A
- Revenue Growth
- TRVI N/A
- ANNX N/A
- 52 Week Low
- TRVI $2.30
- ANNX $1.29
- 52 Week High
- TRVI $7.39
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- TRVI 56.38
- ANNX 38.84
- Support Level
- TRVI $6.37
- ANNX $1.62
- Resistance Level
- TRVI $7.24
- ANNX $2.01
- Average True Range (ATR)
- TRVI 0.42
- ANNX 0.13
- MACD
- TRVI -0.01
- ANNX 0.01
- Stochastic Oscillator
- TRVI 50.38
- ANNX 0.00
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.